ATI RN PHARMACOLOGY PROCTORED EXAM TEST
BANK 2026 VERSION 2.0 - ADVANCED CLINICAL
APPLICATION Comprehensive 150-Question
Practice Exam with Detailed Clinical Rationales
TABLE OF CONTENTS
Section Topic Questions
I Advanced Pharmacokinetics & Pharmacogenomics 1-15
II Complex Medication Administration & High-Alert Drugs 16-30
III Advanced Cardiovascular Pharmacology 31-45
IV Anticoagulation & Hematological Disorders 46-55
V Endocrine & Metabolic Disorders 56-70
VI Respiratory & Critical Care Pharmacology 71-80
VII Neurological, Psychiatric & Pain Management 81-95
VIII Anti-Infectives & Antimicrobial Stewardship 96-110
IX Gastrointestinal, Hepatic & Renal Pharmacology 111-120
X Oncology, Immunosuppression & Biologics 121-130
,Section Topic Questions
XI Emergency, Toxicology & Antidote Therapy 131-140
XII Maternal-Child, Geriatric & Special Populations 141-150
SECTION I: ADVANCED PHARMACOKINETICS & PHARMACOGENOMICS
Q1. A 68-year-old male with a history of chronic kidney disease (Stage 4) is prescribed a
medication that is 95% protein-bound and primarily eliminated renally. His serum albumin is 2.8
g/dL (normal: 3.5-5.0 g/dL). Which pharmacokinetic alteration should the nurse anticipate that
would most significantly increase the risk of adverse effects?
A) Decreased volume of distribution leading to lower peak concentrations
B) Increased free fraction of the drug due to hypoalbuminemia and decreased renal clearance
C) Enhanced first-pass metabolism resulting in reduced bioavailability
D) Accelerated hepatic metabolism due to enzyme induction
Correct Answer: B
Rationale: This patient has two major risk factors for drug toxicity: hypoalbuminemia
(decreased protein binding leads to increased free drug fraction) and stage 4 CKD (decreased
renal elimination). The combination of increased free drug and reduced clearance significantly
increases the risk of adverse effects. Option A is incorrect because hypoalbuminemia actually
increases volume of distribution. Option C is incorrect because first-pass metabolism primarily
affects oral bioavailability, not protein binding. Option D is incorrect as CKD does not accelerate
hepatic metabolism.
Q2. A nurse is caring for a patient who is a CYP2D6 poor metabolizer and is prescribed
codeine 30 mg every 4-6 hours for post-operative pain. After 48 hours, the patient reports
inadequate pain relief. Which statement best explains the therapeutic failure?
A) The patient requires a higher dose because CYP2D6 induces codeine metabolism
B) Codeine is a prodrug requiring CYP2D6-mediated conversion to morphine; poor metabolizers
have reduced analgesic effect
,C) The patient has developed tolerance to codeine requiring dose escalation
D) Codeine is primarily metabolized by CYP3A4, and this patient has enhanced metabolism
Correct Answer: B
Rationale: Codeine is a prodrug that requires conversion to its active metabolite, morphine, via
the CYP2D6 enzyme. Poor metabolizers (approximately 5-10% of the population) have reduced
or absent CYP2D6 activity and derive little to no analgesic benefit from codeine. Option A is
incorrect because CYP2D6 does not induce its own metabolism. Option C is incorrect because
tolerance takes longer to develop. Option D is incorrect because codeine is primarily
metabolized by CYP2D6, not CYP3A4.
Q3. A patient with atrial fibrillation is prescribed warfarin. The patient's CYP2C9 genotype
reveals *2/*3 polymorphism. Which of the following represents the most appropriate clinical
action based on pharmacogenetic testing?
A) Initiate therapy with standard warfarin dosing and monitor INR weekly
B) Initiate therapy with a reduced warfarin dose and monitor INR frequently
C) Initiate therapy with an increased warfarin dose and monitor INR daily
D) Avoid warfarin completely and prescribe an alternative anticoagulant
Correct Answer: B
Rationale: CYP2C9*2 and *3 alleles result in reduced enzyme activity, leading to decreased
warfarin metabolism. Patients with these polymorphisms require lower warfarin doses and are
at increased risk of bleeding. The FDA recommends reduced initial doses and frequent INR
monitoring. Option A is incorrect because standard dosing would likely cause supratherapeutic
INR. Option C is incorrect as increased dosing would be dangerous. Option D is overly aggressive
as warfarin can still be used with appropriate dose adjustments.
Q4. A nurse is administering phenytoin to a patient with status epilepticus. The patient's
serum albumin is 2.5 g/dL. The total phenytoin level is reported as 8 mcg/mL (therapeutic
range: 10-20 mcg/mL). Which action should the nurse take?
A) Increase the phenytoin dose to achieve a total level of 15 mcg/mL
B) Calculate the corrected phenytoin level using the patient's albumin level
C) Discontinue phenytoin and switch to levetiracetam
D) Maintain current dosing as the level is appropriate for this patient
, Correct Answer: B
Rationale: Phenytoin is highly protein-bound (90%). In patients with hypoalbuminemia, the
total phenytoin level underestimates the free (active) drug concentration. A corrected
phenytoin level should be calculated using the patient's albumin level. The corrected level =
measured total level / [(0.2 × albumin) + 0.1]. Option A is incorrect as increasing the dose based
on total level could cause toxicity. Option C is overly aggressive and not indicated. Option D is
incorrect because the total level does not accurately reflect free drug concentration in
hypoalbuminemic patients.
Q5. A patient with liver cirrhosis (Child-Pugh Class C) is prescribed a medication that
undergoes extensive hepatic metabolism. Which pharmacokinetic alteration should the nurse
anticipate?
A) Increased hepatic clearance and decreased half-life
B) Decreased hepatic clearance, increased half-life, and increased bioavailability
C) No significant change in pharmacokinetics
D) Increased renal clearance and decreased volume of distribution
Correct Answer: B
Rationale: Severe liver cirrhosis (Child-Pugh Class C) results in decreased hepatic metabolism,
reduced first-pass effect (increased oral bioavailability), and prolonged half-life. This significantly
increases the risk of drug accumulation and toxicity. Option A is incorrect because liver disease
decreases, not increases, hepatic clearance. Option C is incorrect as liver disease significantly
alters pharmacokinetics. Option D is incorrect as renal clearance is not typically increased in
liver disease.
Q6. A patient is receiving intravenous vancomycin. The medication is known to have a half-
life of 6 hours in patients with normal renal function. The patient's creatinine clearance is 25
mL/min. Which statement best describes the expected pharmacokinetic alteration?
A) The half-life will be decreased due to increased renal clearance
B) The half-life will be prolonged due to decreased renal clearance
C) The half-life will remain unchanged as vancomycin is primarily hepatically metabolized
D) The volume of distribution will increase, decreasing the half-life
Correct Answer: B
BANK 2026 VERSION 2.0 - ADVANCED CLINICAL
APPLICATION Comprehensive 150-Question
Practice Exam with Detailed Clinical Rationales
TABLE OF CONTENTS
Section Topic Questions
I Advanced Pharmacokinetics & Pharmacogenomics 1-15
II Complex Medication Administration & High-Alert Drugs 16-30
III Advanced Cardiovascular Pharmacology 31-45
IV Anticoagulation & Hematological Disorders 46-55
V Endocrine & Metabolic Disorders 56-70
VI Respiratory & Critical Care Pharmacology 71-80
VII Neurological, Psychiatric & Pain Management 81-95
VIII Anti-Infectives & Antimicrobial Stewardship 96-110
IX Gastrointestinal, Hepatic & Renal Pharmacology 111-120
X Oncology, Immunosuppression & Biologics 121-130
,Section Topic Questions
XI Emergency, Toxicology & Antidote Therapy 131-140
XII Maternal-Child, Geriatric & Special Populations 141-150
SECTION I: ADVANCED PHARMACOKINETICS & PHARMACOGENOMICS
Q1. A 68-year-old male with a history of chronic kidney disease (Stage 4) is prescribed a
medication that is 95% protein-bound and primarily eliminated renally. His serum albumin is 2.8
g/dL (normal: 3.5-5.0 g/dL). Which pharmacokinetic alteration should the nurse anticipate that
would most significantly increase the risk of adverse effects?
A) Decreased volume of distribution leading to lower peak concentrations
B) Increased free fraction of the drug due to hypoalbuminemia and decreased renal clearance
C) Enhanced first-pass metabolism resulting in reduced bioavailability
D) Accelerated hepatic metabolism due to enzyme induction
Correct Answer: B
Rationale: This patient has two major risk factors for drug toxicity: hypoalbuminemia
(decreased protein binding leads to increased free drug fraction) and stage 4 CKD (decreased
renal elimination). The combination of increased free drug and reduced clearance significantly
increases the risk of adverse effects. Option A is incorrect because hypoalbuminemia actually
increases volume of distribution. Option C is incorrect because first-pass metabolism primarily
affects oral bioavailability, not protein binding. Option D is incorrect as CKD does not accelerate
hepatic metabolism.
Q2. A nurse is caring for a patient who is a CYP2D6 poor metabolizer and is prescribed
codeine 30 mg every 4-6 hours for post-operative pain. After 48 hours, the patient reports
inadequate pain relief. Which statement best explains the therapeutic failure?
A) The patient requires a higher dose because CYP2D6 induces codeine metabolism
B) Codeine is a prodrug requiring CYP2D6-mediated conversion to morphine; poor metabolizers
have reduced analgesic effect
,C) The patient has developed tolerance to codeine requiring dose escalation
D) Codeine is primarily metabolized by CYP3A4, and this patient has enhanced metabolism
Correct Answer: B
Rationale: Codeine is a prodrug that requires conversion to its active metabolite, morphine, via
the CYP2D6 enzyme. Poor metabolizers (approximately 5-10% of the population) have reduced
or absent CYP2D6 activity and derive little to no analgesic benefit from codeine. Option A is
incorrect because CYP2D6 does not induce its own metabolism. Option C is incorrect because
tolerance takes longer to develop. Option D is incorrect because codeine is primarily
metabolized by CYP2D6, not CYP3A4.
Q3. A patient with atrial fibrillation is prescribed warfarin. The patient's CYP2C9 genotype
reveals *2/*3 polymorphism. Which of the following represents the most appropriate clinical
action based on pharmacogenetic testing?
A) Initiate therapy with standard warfarin dosing and monitor INR weekly
B) Initiate therapy with a reduced warfarin dose and monitor INR frequently
C) Initiate therapy with an increased warfarin dose and monitor INR daily
D) Avoid warfarin completely and prescribe an alternative anticoagulant
Correct Answer: B
Rationale: CYP2C9*2 and *3 alleles result in reduced enzyme activity, leading to decreased
warfarin metabolism. Patients with these polymorphisms require lower warfarin doses and are
at increased risk of bleeding. The FDA recommends reduced initial doses and frequent INR
monitoring. Option A is incorrect because standard dosing would likely cause supratherapeutic
INR. Option C is incorrect as increased dosing would be dangerous. Option D is overly aggressive
as warfarin can still be used with appropriate dose adjustments.
Q4. A nurse is administering phenytoin to a patient with status epilepticus. The patient's
serum albumin is 2.5 g/dL. The total phenytoin level is reported as 8 mcg/mL (therapeutic
range: 10-20 mcg/mL). Which action should the nurse take?
A) Increase the phenytoin dose to achieve a total level of 15 mcg/mL
B) Calculate the corrected phenytoin level using the patient's albumin level
C) Discontinue phenytoin and switch to levetiracetam
D) Maintain current dosing as the level is appropriate for this patient
, Correct Answer: B
Rationale: Phenytoin is highly protein-bound (90%). In patients with hypoalbuminemia, the
total phenytoin level underestimates the free (active) drug concentration. A corrected
phenytoin level should be calculated using the patient's albumin level. The corrected level =
measured total level / [(0.2 × albumin) + 0.1]. Option A is incorrect as increasing the dose based
on total level could cause toxicity. Option C is overly aggressive and not indicated. Option D is
incorrect because the total level does not accurately reflect free drug concentration in
hypoalbuminemic patients.
Q5. A patient with liver cirrhosis (Child-Pugh Class C) is prescribed a medication that
undergoes extensive hepatic metabolism. Which pharmacokinetic alteration should the nurse
anticipate?
A) Increased hepatic clearance and decreased half-life
B) Decreased hepatic clearance, increased half-life, and increased bioavailability
C) No significant change in pharmacokinetics
D) Increased renal clearance and decreased volume of distribution
Correct Answer: B
Rationale: Severe liver cirrhosis (Child-Pugh Class C) results in decreased hepatic metabolism,
reduced first-pass effect (increased oral bioavailability), and prolonged half-life. This significantly
increases the risk of drug accumulation and toxicity. Option A is incorrect because liver disease
decreases, not increases, hepatic clearance. Option C is incorrect as liver disease significantly
alters pharmacokinetics. Option D is incorrect as renal clearance is not typically increased in
liver disease.
Q6. A patient is receiving intravenous vancomycin. The medication is known to have a half-
life of 6 hours in patients with normal renal function. The patient's creatinine clearance is 25
mL/min. Which statement best describes the expected pharmacokinetic alteration?
A) The half-life will be decreased due to increased renal clearance
B) The half-life will be prolonged due to decreased renal clearance
C) The half-life will remain unchanged as vancomycin is primarily hepatically metabolized
D) The volume of distribution will increase, decreasing the half-life
Correct Answer: B
